Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details) - Development Derivative Liability - Fair Value, Level 3 - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value at beginning of period	$ 0	$ 11,607	$ 27,726	$ 0
Non-cash research and development expense	0	5,702	4,951	11,497
Cash receipts from SFJ	0	750	750	2,250
Change in the fair value of development derivative liability	0	3,328	(33,427)	7,640
Fair value at end of period	$ 0	$ 21,387	$ 0	$ 21,387